Working… Menu

Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03189836
Recruitment Status : Recruiting
First Posted : June 16, 2017
Last Update Posted : September 4, 2019
Information provided by (Responsible Party):
Unum Therapeutics Inc.

Brief Summary:
This is a phase 1, multi-center, single-arm, open-label study evaluating the safety and anti-lymphoma activity of an autologous T cell product (ACTR707) in combination with rituximab in subjects with refractory or relapsed CD20+ B cell lymphoma.

Condition or disease Intervention/treatment Phase
Lymphoma Biological: ACTR707 Biological: rituximab Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 Study of ACTR707, an Autologous T Cell Product, in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20+ B Cell Lymphoma
Actual Study Start Date : October 4, 2017
Estimated Primary Completion Date : January 2021
Estimated Study Completion Date : March 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma
Drug Information available for: Rituximab

Arm Intervention/treatment
Experimental: ACTR707 in combination with rituximab Biological: ACTR707
autologous T cell product

Biological: rituximab
CD20-directed cytolytic antibody

Primary Outcome Measures :
  1. Safety as assessed by dose limiting toxicities (DLTs) [ Time Frame: 28 days ]
    Dose-limiting toxicities, MTD, incidence and severity of AEs and clinically significant abnormalities of laboratory values

  2. Determination of maximum tolerated dose and proposed recommended Phase 2 dose [ Time Frame: 24 weeks ]

Secondary Outcome Measures :
  1. Anti-lymphoma activity as measured by overall response rate [ Time Frame: 24 weeks ]
  2. Anti-lymphoma activity as measured by duration of response [ Time Frame: 24 weeks ]
  3. Anti-lymphoma activity as measured by progression-free survival [ Time Frame: 24 weeks ]
  4. Anti-lymphoma activity as measure by overall survival [ Time Frame: 24 weeks ]
  5. Assessment of persistence of ACTR707 as measured by flow cytometry and qPCR [ Time Frame: 24 weeks ]
  6. Assessment of ACTR707 phenotype and function as measured by flow cytometry [ Time Frame: 24 weeks ]
  7. Assessment of inflammatory markers and cytokines/chemokines [ Time Frame: 24 weeks ]
    Cytokines and Inflammatory markers

  8. Rituximab PK [ Time Frame: 24 weeks ]
    Rituximab plasma concentration

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • signed written informed consent obtained prior to study procedures
  • histologically-confirmed relapsed or refractory CD20+ B-cell lymphoma of one of the following types, with documented disease progression or recurrence following the immediate prior therapy: DLBCL (regardless of cell of origin or underlying molecular genetics), MCL, PMBCL, Gr3b-FL, TH-FL (prior dx of FL before transforming to DLBCL).
  • biopsy-confirmed CD20+ expression of the underlying malignancy with disease progression following immediate prior therapy
  • at least 1 measurable lesion on imaging.
  • must have received adequate prior therapy for the underlying CD20+ B-cell lymphoma, defined as an anti-CD20 mAb in combination with an anthracycline-containing chemotherapy regimen (i.e. chemo-immunotherapy) and at least one of the following:

    • biopsy-proven refractory disease after frontline chemo-immunotherapy
    • relapse within 1 year from frontline chemo-immunotherapy and ineligible for autologous hematopoietic stem cell transplant (auto-HSCT)
    • for subjects with DLBCL, PMBCL, and Gr3b-FL: relapsed or refractory disease following at least 2 prior regimens or following an auto-HSCT
    • for subjects with TH-FL: relapsed or refractory disease following at least 2 prior regimens or following an auto-HSCT. At least 1 prior regimen with an anti-CD20 mAb in combination with chemotherapy is required following documented transformation
    • for subjects with MCL (confirmed with cyclin D1 expression or evidence of t(11;14) by cytogenetics, fluorescent in situ hybridization (FISH) or polymerase chain reaction (PCR): relapsed or refractory disease after at least 1 prior regimen with chemo-immunotherapy (prior auto-HSCT is allowable)
  • ECOG 0 or 1
  • life expectancy of at least 6 months
  • platelet count greater than 50,000/µL

Exclusion Criteria:

  • known active central nervous system (CNS) involvement by malignancy.
  • prior treatment as follows:

    • alemtuzumab within 6 months of enrollment
    • fludarabine, cladribine, or clofarabine within 3 months of enrollment
    • external beam radiation within 2 weeks of enrollment
    • mAb (including rituximab) within 2 weeks of enrollment
    • other lymphotoxic chemotherapy (including steroids except as below) within 2 weeks of enrollment
    • experimental agents within 3 half-lives prior to enrollment, unless progression is documented on therapy
  • clinically significant cardiac disease
  • clinically significant active infection
  • clinically significant CNS disorder
  • clinical history, prior diagnosis, or overt evidence of autoimmune disease
  • known bone marrow involvement due to underlying malignant disease, in dose-escalation phase only

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03189836

Layout table for location contacts
Contact: Francis Payumo 530-868-6471
Contact: Patty Harris

Layout table for location information
United States, Arizona
Banner MD Anderson Cancer Center Recruiting
Gilbert, Arizona, United States, 85234
Contact: Javier Munoz, MD, MS, FACS    480-256-6444   
Contact: Sheila Myers, BSN, RN    480-256-5485   
United States, Connecticut
Yale University Recruiting
New Haven, Connecticut, United States, 06520
Contact: Iris Isufi, MD    203-200-4363   
Contact: Alexandra Dormal, RN    203-833-2701   
United States, Georgia
Emory University, Winship Cancer Institute Recruiting
Atlanta, Georgia, United States, 30322
Contact: Clinical Trials Office    404-778-4400      
Contact: Amanda Hutchinson-Rzepka    404-778-3935   
United States, Indiana
Indiana Bone and Marrow Transplantation Recruiting
Indianapolis, Indiana, United States, 46327
Contact: Luke P Akard, MD    317-528-5500      
Contact: Lorraine "Kay" Harvey, BSN RN CCRN CCRP    317-528-5500   
United States, Maryland
University of Maryland Recruiting
Baltimore, Maryland, United States, 21201
Contact: Surabh Dahiya, MD, FACP    410-328-1230   
Contact: Janaiya Samuels, MS, RN    410-328-2341   
United States, Minnesota
University of Minnesota Recruiting
Minneapolis, Minnesota, United States, 55455
Contact: Veronika Bachanova, MD    612-625-5469   
Principal Investigator: Veronika Bachanova, MD         
United States, Ohio
Ohio State University Recruiting
Columbus, Ohio, United States, 43210
Contact: Samantha M Jaglowski, MD    614-293-3316   
United States, Tennessee
Tennessee Oncology - Nashville Recruiting
Nashville, Tennessee, United States, 37203
Contact: Kristina Salfarlie   
Principal Investigator: Ian W Flinn, MD, PhD         
United States, Texas
The University of Texas MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Brittani Pulsifer, MSN, FNP-C    713-794-1062   
Contact: Wirt Montinez, BSN    713-745-7070   
Sponsors and Collaborators
Unum Therapeutics Inc.
Layout table for investigator information
Study Director: Jessica Sachs, MD Unum Therapeutics Inc.

Layout table for additonal information
Responsible Party: Unum Therapeutics Inc. Identifier: NCT03189836     History of Changes
Other Study ID Numbers: ATTCK-20-03
First Posted: June 16, 2017    Key Record Dates
Last Update Posted: September 4, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Unum Therapeutics Inc.:
B cell
T cell
T cell product
adoptive T cells
gene therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents